• English
  • Korean
  • Chinese
市場調査レポート - 236838

造影剤の世界市場

Imaging Agents

発行 Global Industry Analysts, Inc.
出版日 ページ情報 英文 450 Pages
価格

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。 PDFのダウンロード・閲覧には Adobe Digital Editions が必要となります。ご購入頂いた場合、同Adobe Digital Editions (ご購入時無償配布)をPCにインストールして頂き、ダウンロードを行ったPC上のみでの閲覧と、1回のプリントアウトが可能となっております。ご不明な点につきましてはお問合せください。

造影剤の世界市場 Imaging Agents
出版日: 2012年02月01日 ページ情報: 英文 450 Pages
概要

当レポートでは、造影剤の世界市場を製品部門別に分析し、米国/カナダ/日本/欧州/アジア太平洋/中東/南米の包括的な地域別分析を提供し、2009-2017年間の年間業績を推定/予測するとともに6年間の歴史的分析、及び主要/ニッチプレーヤ55社の企業プロファイルを盛り込み、概略下記の構成でお届けいたします。

第1章 イントロダクション、方法論、製品定義

第2章 業界概要

  • 業界の展望
  • 景気後退の影響を受ける医用画像業界
  • 標的画像:変革者になり得る?
  • 成長を促進する発展途上国
  • 造影剤の解説
  • 成長促進要因
  • 成長阻害要因
  • 造影剤の変化する動向
  • 造影剤:前途の大きな成長
  • 非電離画像技術の上昇
  • 融合画像モダリティ:多大な臨床的利点
  • 放射性医薬品:新種のツール
  • 注目を集めるナノマテリアル
  • 価格設定動向
  • 要約
  • 長所と短所
  • 価格上昇のプラスの要因
  • 価格下落を招くマイナス要因
  • 償還
  • 保護の下

第3章 市場のトレンドと問題

  • 値下げの過熱
  • X線コントラスト剤:下落中の部門
  • MRIコントラスト剤:主役
  • MRIの急増によりもたらされる影響
  • 超音波コントラスト剤:四半部の急上昇のスター
  • 成長中の市場競争は初期の課題
  • PET:放射性医薬品の主な成長牽引力
  • 核医学:放射性医薬品の潜在的成長手段
  • 主要な心臓/腫瘍学向け放射性医薬品

第4章 競合

  • 市場構造
  • 新興MRI市場における有力者
  • Bayer Schering Pharma AG:MRIコントラスト剤の草分け的開発業者
  • 競合的シナリオ

第5章 技術的躍進

  • 分子造影剤:ぎりぎりの限界
  • コントラスト剤としての過分極ガスの可能性
  • アルツハイマー病の分野にて喜ばしい影響をもたらす造影剤
  • テクネチウム99m:中枢神経系画像化の画期的なコントラスト剤
  • 放射性医薬品スキャン向けの新規造影剤
  • マルチモダル・イメージ記録:コントラスト剤の不一致への対抗
  • コントラスト剤の正確な到達を確実にする生理食塩水洗浄

第6章 製品概要

  • コントラスト剤
  • イメージング剤
  • MRI:コントラスト剤の新たな時代を築く
  • 次世代非イオン性コントラスト剤:イントロダクション
  • コントラスト剤の選択:重大な決定
  • イメージング剤の選択に影響する要因
  • 分類法
  • コントラスト剤のタイプ
  • 診療用放射性医薬品

第7章 部門別レビュー

  • コントラスト剤
  • コントラスト剤の人気ブランド
  • X線用コントラスト剤
  • MRI用コントラスト剤
  • 超音波用コントラスト剤
  • 診療用放射性医薬品
  • 免疫抱合体

第8章 技術的動態

第9章 製品発売

第10章 最近の業界活動

第11章 戦略的企業発展:展望材料

第12章 製品紹介/革新:歴史的展望材料

第13章 主要プレーヤへの焦点

第14章 世界市場展望

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • その他
  • アジア太平洋
  • 中東
  • 南米

第15章 競合状況

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

Description

This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following Product Segments: Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 55 companies including many key and niche players such as AMAG Pharmaceuticals Inc., Bayer Schering Pharma AG, Bracco Group, Covidien, Daiichi Sankyo Company Limited, Eisai Co., Ltd, EUSA Pharma, Inc., GE Healthcare, Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • A. Contrast Media
        • X-Ray Contrast Media
        • Magnetic Resonance Imaging (MRI) Contrast Media
        • Ultrasound Contrast Media
    • B. Diagnostic Radiopharmaceuticals

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Industry Outlook
  • Medical Imaging Industry Under the Impact of Economic Downturn
  • Targeted Imaging - A Game Changer in the Making?
  • Developing Countries to Spur Growth
  • A Quick Primer On Imaging Agents
  • Growth Drivers
  • Growth Inhibitors
  • Changing Dynamics of Imaging Agents
  • Imaging Agents: Significant Growth Ahead
  • Rise of Non-Ionizing Imaging Techniques
  • Fusion Imaging Modalities: Greater Clinical Benefits
    • Radioactive Isotopes Utilized in PET & SPECT Imaging Procedures
  • Radiopharmaceuticals-An Exotic Tool
  • Nanomaterials Taking the Center Stage
    • Gadolinium Coated Nanoparticles- A Promising Imaging Agent
  • A Peek Into Pricing Dynamics
  • A Synoptic Overview
  • Pros & Cons
  • Positive Factors Driving Prices
  • Negative Factors Bearing Down on Prices
  • Reimbursements
  • "Under the Umbrella"
    • Europe
    • United States

2. MARKET TRENDS & ISSUES

  • Falling Prices Turn On the Heat
  • X-Ray Contrast Media: Declining Sector
  • MRI Contrast Media: Playing at Center Court
  • Impact Wielded by Ballooning MRI Practices
  • Ultrasound Contrast Media: A Rising Star in the Quadrant
  • Fledging Market Battles Teething Challenges
  • PET: A Prime Growth Driver for Radiopharmaceuticals
  • Nuclear Medicine: A Potential Growth Avenue for Radiopharmaceuticals
  • Select Cardiology and Oncology Radiopharmaceuticals

3. COMPETITION

  • Market Structure
  • Big Guns in the Emerging MRI Market
  • Bayer Schering Pharma AG: A Pioneering Developer of MRI Contrast Agents
  • Competitive Scenario
    • Table 1: Worldwide Imaging Agents Market (2009): Percentage Breakdown of Value Sales for Leading Players- GE Healthcare, Bracco, Covidien, Bayer Schering Pharma, and Others (includes corresponding Graph/Chart)
    • Table 2: X-ray Medical Contrast Media Market Worldwide (2009): Percentage Breakdown of Sales for GE Healthcare, Bracco, Covidien, Bayer Schering Pharma and Others (includes corresponding Graph/Chart)
    • Table 3: MRI Contrast Media Market Worldwide (2009): Percentage Breakdown of Sales for Bayer Schering Pharma, GE Healthcare, Bracco, Covidien and Others (includes corresponding Graph/Chart)
    • Table 4: Radiopharmaceutical Contrast Media Market Worldwide: Percentage Share of Leading Players for 2007 - GE Healthcare, Bristol-Myers Squibb, Mallinckrodt/ Covidien, MDS Nordion and Others (Revenue Share) (includes corresponding Graph/Chart)

4. TECHNOLOGY BREAKTHROUGHS

  • Molecular Imaging Agents: The Outer Limits
  • On Cards: Hyperpolarized Gases as Contrast Agents
  • Imaging Agents Make a Welcome Impact in the Field of Alzheimer's Disease
  • Technetium-99m: A Breakthrough Contrast Agent for CNS Imaging
  • A New Imaging Agent for Radiopharmaceutical Scans
  • Multi-Modal Image Registration: Combating Contrast Medium Inconsistencies
  • Saline Flushes To Help Ensure Accurate Delivery of Contrast Agents

5. PRODUCT OVERVIEW

  • Contrast Agents
  • Contrast Media: How Do They Function?
    • Where Are They Used...?
  • Evolution of Contrast Media: A Profile
    • Bismuth Nitrate: Beginning of Contrast Agents
  • Imaging Agents: Significant Developments in the Last Fifty Years
  • Schering Develops First Intravenous Contrast Agent
  • MRI: Creating a New Era for Contrast Agents
  • A Peek into the Finer Points of Differences Among Contrast Media
      • Viscosity
      • Osmolality
      • Chemotoxicity
  • Second Generation Non-Ionic Contrast Agents: An Introduction
  • Choice of the Contrast Medium: A Weighty Decision
  • Factors affecting choice of Imaging Agents
  • Taxonomy
  • Types of Contrast Media
  • X-Ray Contrast Medium
    • First Generation High Osmolar Contrast Media
    • Second Generation Low Osmolar Contrast Media or LOCM
    • Table 5: Comparative Analysis of Structure of Non-ionic and ionic X-ray Contrast Media
  • MRI Contrast Medium
    • Role of Contrast Enhancement in MR Angiography (MRA)
    • MRI Contrast Agents for the Liver
      • Paramagnetic extracellular contrast agents
      • Hepatobiliary Gadolinium Chelates
      • Superparamagnetic Iron Oxide Particles
  • Ultrasound Contrast Medium
    • Ultrasonographic Contrast Media: What Are They?
    • Ultrasound Contrast Enhancement in Cardiology
    • Functionalities of Vascular Ultrasound Contrast Agents
  • Diagnostic Radiopharmaceuticals
    • Key Radioactive Isotopes used as Diagnostic Radiopharmaceuticals
      • A Delineate of Diagnostic Radiopharmaceuticals
      • Diagnostic Radiopharmaceuticals: A Technical Run-Through
      • Applications

6. A SEGMENTAL REVIEW

  • Contrast Media
  • Popular Brands of Contrast Agents
  • X-ray Contrast Media
    • Market Scenario
  • MRI Contrast Media
    • Market Scenario
  • Ultrasound Contrast Media
    • Market Overview
    • Competitive Scenario
  • Diagnostic Radiopharmaceuticals
    • Market Overview
  • Immunoconjugates
    • Market Overview

7. TECHNOLOGY DYNAMICS

  • Proprietary Technologies Making Significant In-Roads
  • Advanced Magnetics' Proprietary Colloidal Superparamagnetic Particle Technology
  • Enzon's Single Chain Antigen-Binding Technology
  • Immunomedics' Antibody Technology
    • First Generation
    • Second Generation
    • Third Generation
  • NeoRx's "Painting the Target" Technology
    • Stage - I
    • Stage - II
    • Stage - III
  • Gas Encapsulation Technology for Ultrasound Contrast Media
  • Pharmacyclics' Texaphyrin Technology
  • Regulatory Bodies
  • Ultrasound Contrast Agents Are Drugs, Not Devices - Rules US FDA
  • Entry Barriers
  • Research Driven Markets
  • Highly Competitive Market
  • Economies of Scale
  • Substitutes in Agents Manufacturing
  • New X-ray Diagnostic Agents
  • Amide-based Macrocyclic Ligands - Potential MRI Agents
  • Gadolinium (III) Complexes - Potential MRI Contrast Agents
  • Metal-Containing Compounds Act As Potential Contrast Agents
    • Therapeutic Applications
    • Diagnostic Applications
  • Magnetic Gels as Potential MRI Contrast Agents
  • PFCs as Diagnostic Contrast Agents

8. PRODUCT LAUNCHES

  • GE Healthcare Receives FDA Approval for DaTscan for detecting Dopamine Transporters
  • Targeson Launches Targestar® P-HF
  • GE Healthcare Announces Phase II Study Results of Flutemetamol, the PET Imaging Agent for Brain Imaging
  • GE Healthcare Receives FDA Approval for Cysview, An Optical Imaging Agent for Cystoscopic Detection of Papillary Bladder Cancer
  • INER Develops Imaging Agents for Cerebral Blood Flow
  • Lantheus Medical Imaging Introduces Definity Ultrasound Contrast Imaging Agent in India
  • Sanochemia Pharmazeutika Completes DCP Phase of MRT Imaging Agent, to Introduce Within Major European Markets by 2011
  • Bayer Transfers Liver MRI Contrast Medium Resovist Injection to I'rom Pharmaceutical
  • GE Healthcare Re-Introduces Contrast Agent, OptisonTM
  • Lantheus Medical Imaging Introduces ABLAVAR™ in Canada
  • VisEn Introduces ProSense® 750 FAST and Neutrophil ElastaseTM 680 FAST
  • Bayer Works on Development of MR Contrast Agents for Breast Cancer Diagnosis
  • Lantheus Medical Imaging Introduces ABLAVAR™ MRA Imaging Agent
  • VisEn Introduces Cat B 680 FAST™ Imaging Agent
  • VisEn Medical Introduces GastroSense 750 Fluorescence Imaging Agent
  • VisEn Medical Unveils VivoTag® 645 Red Fluorescent Dye
  • VisEn Medical Launches VivoTag® 680 XL Fluorescent Dye
  • AMAG Pharmaceuticals Unveils Superparamagnetic Iron Oxide Nanopaticles
  • MabCure Unveils Monoclonal Antibodies
  • VisEn Medical Introduces ReninSense680TM FAST
  • VisEn Medical Introduces New VivoTag® 800 and OsteoSense® Imaging Agents
  • VisEn Medical Introduces Annexin-Vivo 750 Imaging Agent
  • VisEn Introduces New Fluorescence Molecular Imaging Agent, IntegriSense™ 750

9. RECENT INDUSTRY ACTIVITY

  • Covidien to Spin Off Pharma Business
  • University of Montana Receives Patents for Two New Brain Imaging Agents
  • Eli Lilly Acquires Avid Radiopharmaceuticals
  • GE Global Research Secures Multi-Year NIH Grant to Develop Nerve Imaging Agent and Imaging System
  • Agfa Healthcare Snaps Insight Agents
  • Nordion to Divest MDS Nordion S.A.
  • Sofie Biosciences Secures Funds for Research on Molecular PET Imaging Agents
  • Aposense Signs Collaboration Agreement With Roche
  • University of Washington to Collaborate with Cardinal Health for Advancement of Molecular Imaging
  • ImaginAb Joins Hand with GE Imanet for Developmental Drug Research
  • Cancer Targeted Technology Inks Agreement with Bayer Pharma for Cancer PET Imaging Agent
  • Lantheus Medical Imaging Wins Global Rights for Gadofosveset Trisodium
  • Avid Radiopharmaceuticals Partners with Siemens PETNET Solutions for Production of Florbetapir F 18
  • VisEn Expands Fluorescence Imaging Intellectual Patent Portfolio through Acquisition of Bayer Schering's Portfolio
  • Cardinal Health Enters into Partnership with ProVision for Cyclotrons
  • Center for Diagnostic Imaging Sets up New Imaging Center
  • ImaginAb Signs Sub Licensing Agreement for huJ591 with BZL Biologics
  • Lantheus Medical Imaging and NTP Radioisotopes Sign Agreement for Molybdenum-99
  • Lantheus Medical Imaging Purchases MS-325 Related Rights from EPIX Pharmaceuticals
  • GE Healthcare Inks Agreement with Nycomed
  • Photocure Secures Reimbursement Approval for Hexvix in Germany
  • Agfa HealthCare to Acquire Insight Agents
  • Eckert & Ziegler Disinvests FCI Contrast Media Business
  • Guerbet Signs Distribution Agreement with Draximage for its Nuclear Medicine Product Range
  • ImaginAb Signs Sub Licensing Agreement for huJ591 with BZL Biologics
  • Lantheus Medical Imaging and NTP Radioisotopes Sign Agreement for Molybdenum-99
  • Lantheus Medical Imaging Purchases MS-325 Related Rights for Select Markets from EPIX Pharmaceuticals
  • MDS Nordion, TRIUMF and University of British Columbia Enter into Partnership
  • Alseres Pharmaceuticals Signs Agreement for Special Protocol Assessment of Altropane
  • Pharmalucence Wins Approval from FDA for Sestamibi Kit
  • Covidien Obtains Approval from Health Canada for Sestamibi Injection
  • MDS Nordion Commences Production of CardioGen-82

10. STRATEGIC CORPORATE DEVELOPMENTS IN PAST - A PERSPECTIVE BUILDER

  • Avista Capital Partners Acquires Bristol-Myers Squibb Medical Imaging
  • Amerinet Awards Contract to Bayer HealthCare
  • Bristol-Myers Squibb Medical Imaging Changes Name to Lantheus Medical Imaging
  • Bayer Schering Secures FDA Marketing Clearance for Primovist®
  • Bracco-Eisai Secures Approval for Iomeron® 350 and Iomeron® 350 Syringe for Use in Dynamic Liver CT
  • Covidien Signs Co-Marketing Deal with PETNET over Nuclear Medicine Therapies
  • EPIX Receives FDA Approval for Vasovist
  • GE Global and NCI Partner to Speed-up Development of Cancer and Heart Disease Diagnosing Nanoparticle Imaging Agents
  • Lantheus Wins Contract from PPP
  • Sanguine to Take over Rockland
  • Starpharma Holdings Enters into an Agreement with Unilever
  • GE Healthcare and Cardinal Health Enter Into a Deal
  • Jubilant to Take Over DRAXIS
  • MTTI and Bexion to Partner for Nanovesicle
  • Otsuka Takes over IPP
  • Wilex Inks Deal with IBA
  • Eusa Pharma Takes Over Cytogen
  • Bracco Group Acquires E-Z-EM
  • EPIX Pharmaceuticals to Resubmit New Drug Application (NDA) for Vasovist
  • Bayer Schering, FutureChem Ink Licensing Deal
  • NuView Radio Pharmaceuticals Inks Agreement for Non- Invasive Imaging Agent
  • Advanced Magnetics Inc Changes Name to AMAG Pharmaceuticals
  • Bracco Diagnostics Inks Agreement with HealthTrust Purchasing Group
  • Bracco Diagnostics Offers MRI Products to HealthTrust Purchasing Group
  • Bayer HealthCare Offers MRI Contrast Agent to HealthTrust
  • Bayer HealthCare Extends Contract with Premier
  • Bayer HealthCare Sets Off US Operations
  • Tyco Healthcare Renamed to Covidien Ltd
  • Covidien Offers Imaging Solutions to MedAssets Supply Chain Systems
  • Siemens, M.D. Anderson Cancer Center Set up Research Centre
  • Bayer, Berlex Merge Operations
  • AION Diagnostics Forays Pre-Clinical Imaging Agent Market
  • ART Acquires Alerion Biomedical
  • EPIX to Merge with Predix
  • Fujifilm Acquires Stake in Daiichi Radioisotope Laboratories
  • Bracco Diagnostics Inks Agreement with Amerinet
  • Vasovist receives Green Signal in Australia
  • AION Diagnostics Develops BioSilicon TM
  • Sonazoid Receives Import Approval

11. PRODUCT INTRODUCTIONS/INNOVATIONS - A HISTORIC PERSPECTIVE BUILDER

  • Insight Agents to Launch Generic Contrast Media Solutions In Europe
  • Researchers Develop First Biocompatible MRI Contrast Agent
  • Signalomics and Invitrogen Collaborate to Develop Nanocrystal Reagents
  • Schering AG Collaborates with Stanford University to Develop Molecular Imaging Agent
  • Schering and Avid to Develop Diagnostic Imaging Agents
  • US National Institutes of Health Develops two PET Imaging Agents

12. FOCUS ON SELECT PLAYERS

  • AMAG Pharmaceuticals, Inc. (USA)
  • Bayer Schering Pharma AG (Germany)
  • Bracco Group (Italy)
  • Covidien (USA)
  • Daiichi Sankyo Company Limited (Japan)
  • Eisai Co Ltd. (Japan)
  • EUSA Pharma, Inc. (UK)
  • GE Healthcare (UK)
  • Guerbet Group (France)
  • Lantheus Medical Imaging (USA)

13. GLOBAL MARKET PERSPECTIVE

    • Table 6: World Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 7: World Historic Review for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 8: World 15-Year Perspective for Imaging Agents by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 9: World Recent Past, Current & Future Analysis for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 10: World Historic Review for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 11: World 15-Year Perspective for Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 12: World Recent Past, Current & Future Analysis for Contrast Media by Product Segments - X-Ray, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 13: World Historic Review for Contrast Media by Product Segments - X-Ray, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 14: World 15-Year Perspective for Contrast Media by Product Segments - Percentage Breakdown of Dollar Sales for X-Ray, MRI and Ultrasound Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 15: World Recent Past, Current & Future Analysis for X-Ray Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 16: World Historic Review for X-ray Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 17: World 15-Year Perspective for X-Ray Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 18: World Recent Past, Current & Future Analysis for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 19: World Historic Review for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 20: World 15-Year Perspective for MRI Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 21: World Recent Past, Current & Future Analysis for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 22: World Historic Review for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 23: World 15-Year Perspective for Ultrasound Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 24: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 25: World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 26: World 15-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Outlook
    • Imaging Centers Feel the Heat During Recession
  • Growth Stimulants
    • Dynamics of Pricing
    • Diagnostic Radiopharmaceuticals
      • Market Scenario
      • Availability of Isotopes: A Tough Challenge
    • Radiopharmaceuticals to Drive Growth
    • Competitive Analysis - Imaging Market
    • Reimbursement Issues
      • Medicare
      • Magnetic Resonance Imaging
    • Regulatory Environment
      • Provisions Regarding Off-Label Usage of Contrast Media
    • Contrast Media
      • X-ray Contrast Media
      • MRI Contrast Media
      • Market Scenario
    • Managed Care Vs MRI Technology Diffusion
      • Ultrasound Contrast Media
  • B. Market Analytics
    • Table 27: US Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 28: US Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 29: US 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Outlook
    • Diagnostic Equipment Market
      • LOCM Products Approved in Canada
  • B. Market Analytics
    • Table 30: Canadian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 31: Canadian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 32: Canadian 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Outlook
    • Reimbursement Issues
  • B. Market Analytics
    • Table 33: Japanese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 34: Japanese Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 35: Japanese 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • Trends
      • Reimbursement
      • Outsourcing of Imaging Diagnostics
    • Distribution Structure
      • Direct Sales
      • License Agreements
      • Distribution Agreements
      • A Price Sensitive Market
    • Macro Environment
      • Germany
      • France
      • Spain & Italy
      • Scandinavia
  • B. Market Analytics
    • Table 36: European Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 37: European Historic Review for Imaging Agents by Geographic Region - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 38: European 15-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 39: European Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 40: European Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 41: European 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Growth Stimulants
  • B. Market Analytics
    • Table 42: French Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 43: French Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 44: French 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) & Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4b. GERMANY

  • Market Analytics
    • Table 45: German Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 46: German Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 47: German 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analytics
    • Table 48: Italian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 49: Italian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 50: Italian 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • Market Analytics
    • Table 51: UK Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 52: UK Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 53: UK 15-Year Perspective for Imaging Agents by Product Segment Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analytics
    • Table 54: Spanish Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 55: Spanish Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 56: Spanish 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analytics
    • Table 57: Russian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment -Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 58: Russian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 59: Russian 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • Market Analytics
    • Table 60: Rest of Europe Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 61: Rest of Europe Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 62: Rest of Europe 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • MRI Market in Asia
    • ANSTO: Leading the Radiopharmaceuticals Market
    • India - A High Potential Market
  • B. Market Analytics
    • Table 63: Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 64: Asia-Pacific Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 65: Asia-Pacific 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

6. THE MIDDLE EAST

  • Market Analytics
    • Table 66: Middle East Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 67: Middle East Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 68: Middle East 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

7. LATIN AMERICA

  • A. Market Analysis
    • Private Sector Boosts Healthcare Segment
  • B. Market Analytics
    • Table 69: Latin American Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 70: Latin American Historic Review for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 71: Latin American 15-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top